Y-Intercept (HK)’s Nuvectis Pharma NVCT Stock Holding History

Y-Intercept (HK)’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,173	Closed	-$147K	–	1646
2024 Q2	$147K	Buy	+23,173	New	+$158K	0.01%	1214

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Y-Intercept (HK)'s NVCT Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Nuvectis Pharma (NVCT) in Q3 2024, closing a stake of 23,173 shares — an estimated $147K sold.

Y-Intercept (HK) first reported a position in NVCT in Q2 2024 and held it in 1 quarter. The position peaked at $147K in Q2 2024. 31 funds tracked by Wall St. Rank hold NVCT as of Q3 2024.

Y-Intercept (HK) reported no remaining Nuvectis Pharma position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 23,173 Nuvectis Pharma shares in Q3 2024, an estimated $147K.
Y-Intercept (HK) first reported a position in Nuvectis Pharma in Q2 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Nuvectis Pharma position peaked at $147K in Q2 2024.
31 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.